Dextromethorphan

# Research Output: Dextromethorphan

## Chemical Identity

**Verified from PubChem CID 5360696:**
- **Molecular formula:** C₁₈H₂₅NO (verified; absent from brief seed data)
- **Molecular weight:** 271.4 g/mol (verified; absent from brief seed data)
- **IUPAC name:** (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.0¹·¹⁰.0²·⁷]heptadeca-2(7),3,5-triene (consistent with brief)
- **InChIKey:** MKXZASYAUGDDCJ-NJAFHUGGSA-N (verified; absent from brief seed data)
- **PubChem CID:** 5360696 (verified; absent from brief seed data)
- **CAS number:** 125-71-3 (web-retrieved; absent from brief seed data)
- **Physical form:** White crystalline powder (free base); marketed as hydrobromide salt
- **Melting point:** 106–108 °C (free base) (web-retrieved [Ref 43])
- **LogP:** 3.61–4.11 (various sources; lipophilic, penetrates CNS readily) [Ref 35]
- **XLogP (IUPHAR):** 3.61 [Ref 35]
- **CAS for hydrobromide monohydrate:** 6700-34-1

**Notes on seed data:** The brief was missing molecular formula, molecular weight, InChIKey, PubChem CID, SMILES, and CAS number. All have now been sourced and confirmed from PubChem. SMILES will be present in the PubChem record but was not returned by the API call; the generation agent should retrieve the SMILES directly from PubChem CID 5360696.

---

## Pharmacology

### Chemical Class and Stereochemistry
Dextromethorphan (DXM) belongs to the morphinan class and is the dextrorotatory enantiomer of levomethorphan. Its levorotatory mirror image, levomethorphan, is a potent mu-opioid analgesic. DXM, by contrast, has minimal mu-opioid receptor activity at therapeutic doses — a key distinction from opioids. It was synthesized specifically to separate antitussive from opioid activity McClure & Daniels (2023 [Ref 16]).

### Receptor Pharmacology

**NMDA Receptor (Primary target):**
DXM is a low-affinity, uncompetitive (open-channel) antagonist at NMDA receptors. It binds within the channel pore at the same site as PCP (phencyclidine). Quantitative binding data from Chou et al. (1999 [Ref 8]):
- DXM Ki at NMDA/PCP site = **7 µM** (rat brain membranes)
- Dextrorphan (DXO) Ki at NMDA/PCP site = **0.9 µM** (rat brain membranes)

IUPHAR data [Ref 35] at GluN2C subunit:
- DXM IC₅₀ = **4.66 × 10⁻⁷ M (466 nM)**, pIC₅₀ = 6.3, channel blocker at pH 6.9

These measurements reflect assay-dependent differences. Dextrorphan (the metabolite) has ~7-8× greater NMDA potency than the parent compound. At supratherapeutic doses, DXO accumulation drives the dissociative-hallucinogenic effects. The uncompetitive mechanism means antagonism increases when the channel is more frequently open (use-dependence) Werling et al. (2007 [Ref 31]).

**Sigma-1 Receptor (High-affinity target):**
DXM is a potent sigma-1 receptor agonist. Sigma-1 receptors are enriched in the limbic system and are implicated in antidepressant activity, neuroplasticity, and emotional regulation.
- DXM Ki at sigma-1 = **205 nM** (rat brain tissue, Chou et al. 1999 [Ref 8])
- DXM Ki at sigma-1 = **521 nM** (cloned Jurkat cells, IUPHAR [Ref 35])
- Dextrorphan Ki at sigma-1 = **144 nM** (Chou et al. 1999 [Ref 8])
- DXM and dextrorphan had low affinity at sigma-2 receptors (Ki = 4–11 µM) [Ref 8]

Sigma-1 receptor agonism is the most likely mechanism underlying DXM's therapeutic benefit in PBA and is a proposed antidepressant mechanism Rosen (2008 [Ref 11]), Werling et al. (2007 [Ref 9]).

**Serotonin Transporter (SERT):**
DXM inhibits SERT with high-to-moderate affinity. Werling et al. (2007 [Ref 9]) confirmed DXM competed with radioligand for SERT binding in rat brain tissue. SERT Ki ≈ 40 nM has been reported in reference databases (web-retrieved). This mechanism underlies the serotonin syndrome risk with serotonergic co-medications and contributes to antidepressant-like effects Lauterbach (2011 [Ref 29]).

**Nicotinic Acetylcholine Receptors (nAChRs):**
DXM and dextrorphan are noncompetitive, reversible blockers of neuronal nAChRs. Hernandez et al. (2000 [Ref 27]) demonstrated:
- Both DXM and dextrorphan block α3β4 nAChR function via channel pore binding (not at agonist site)
- DXM is approximately 9-fold less potent than mecamylamine at blocking nAChR
- Dextrorphan is 3× less potent than DXM at α3β4 nAChR
- Also active at α4β2 and α7 subtypes [Ref 22]
- nAChR blockade may contribute to smoking cessation potential

**Voltage-Gated Calcium Channels:**
Carpenter et al. (1988 [Ref 19]) demonstrated DXM and dextrorphan decrease voltage-gated Ca²⁺ uptake in brain synaptosomes:
- DXM half-maximal inhibition of N-type (synaptosomal) Ca²⁺ uptake: **48 µM**
- Dextrorphan: **200 µM**
- Concentrations similar to those protective from excitotoxicity — suggesting Ca²⁺ channel blockade contributes to neuroprotection

**Mu-Opioid Receptor:**
⚠️ **FLAG FOR REVIEW:** The brief lists "Mu-opioid receptor agonist" as a pharmacological class. This is contested in the literature. StatPearls [Ref 22] explicitly states DXM "lacks the phenanthrene structure of classical opioids and has minimal mu (μ)-opioid receptor activity." However, Lauterbach (2011 [Ref 29]) lists mu-opioid among DXM's receptor actions. The consensus is that DXM has very weak, clinically insignificant mu-opioid activity compared to its enantiomer levorphanol. DXM was specifically developed as a **non-narcotic** antitussive with no meaningful opioid agonism at therapeutic doses. The "Mu-opioid receptor agonist" classification in the brief appears to be incorrect or significantly overstated and warrants editorial correction.

**Additional Targets (from Lauterbach 2011 [Ref 29]):**
- β-adrenergic receptors
- α₂-adrenergic receptors
- Serotonin 1B/1D receptors
- Muscarinic acetylcholine receptors
- Norepinephrine transporter (NET) — blockade reported

### Metabolism and CYP Enzymes

DXM undergoes extensive first-pass hepatic metabolism, primarily via **CYP2D6**. The metabolic pathway (Silva & Dinis-Oliveira 2020 [Ref 21]):

1. **O-demethylation (CYP2D6):** DXM → **dextrorphan (DXO)** — the major active metabolite with significantly greater NMDA potency
2. **N-demethylation (CYP3A4):** DXM → 3-methoxymorphinan
3. **Bidirectional:** The O/N-demethylation order can reverse, yielding 3-methoxymorphinan as an intermediate product
4. **Glucuronidation (UGT):** DXO and 3-hydroxymorphinan form glucuronide conjugates

**CYP2D6 Genetic Polymorphism — Critical Clinical Factor:**
CYP2D6 activity varies enormously between individuals (Zhou SF 2009 [Ref 15]; Schadel et al. 1995 [Ref 18]):

| Phenotype | Prevalence | DXM Bioavailability | DXM t½ |
|-----------|-----------|---------------------|---------|
| Extensive metabolizers (EM) | ~90% | 1–2% | 2–3 hours |
| Poor metabolizers (PM) | ~8–10% Caucasians | 60–80% | 15–20 hours |
| With quinidine (CYP2D6 inhibitor) | — | Markedly increased | 16.4 hours |

In PMs, DXM accumulates in plasma to levels far higher than in EMs, producing stronger and longer-lasting psychoactive effects. This explains why the same dose produces profoundly different experiences in different individuals. Quinidine is co-formulated with DXM (Nuedexta) specifically to inhibit CYP2D6 and raise DXM bioavailability therapeutically.

**Elimination:** Predominantly renal, as glucuronide and sulfate conjugates. Less than 1% of parent DXM is excreted unchanged.

**Protein Binding:** Not quantified from primary sources retrieved. DrugBank data unavailable (403 access block). [FLAG: protein binding data absent — requires further retrieval.]

---

## History

**Discovery and Synthesis:**
The racemic parent compound racemorphan was first described in Swiss and US patent applications by Hoffmann-La Roche in 1946 and 1947 respectively; a patent was granted in 1950 (web-retrieved [Ref 42]). Resolution of the two enantiomers with tartaric acid was published in 1952. The dextrorotatory isomer (DXM) was successfully tested in 1954 in research partially funded by the US Navy and CIA as part of a program to identify non-addictive substitutes for codeine McClure & Daniels (2023 [Ref 16]).

**FDA Approval:**
DXM was approved by the FDA in **1958** as the first non-opioid/non-narcotic cough suppressant. It replaced codeine as the dominant OTC antitussive and has remained the most widely used OTC cough suppressant globally since that time McClure & Daniels (2023 [Ref 16]).

**Recognition of Abuse Potential:**
Recreational misuse emerged relatively early. Abuse was noted in the literature by the 1960s–1970s. The drug's OTC availability made it widely accessible to adolescents and young adults. By the 2000s, there was an alarming increase in reported abuse cases, predominantly among teenagers Mutschler et al. (2010 [Ref 6]). The Consumer Healthcare Products Association (CHPA) collaborated with retailers to institute voluntary age-restriction sales programs, and individual US states began legislating age limits for purchase.

**Regulatory Milestones:**
- 1958: FDA OTC approval for antitussive use
- 2010: FDA approval of **Nuedexta** (DXM/quinidine) for pseudobulbar affect — first FDA-approved PBA treatment
- 2022: FDA approval of **Auvelity** (AXS-05; DXM/bupropion) for major depressive disorder in adults [Ref 14]
- DXM/quinidine is also one of 5 FDA-approved treatments for ALS (for PBA symptoms in ALS) [Ref 38 context]

---

## Subjective Effects

No controlled human dose-response studies of recreational DXM use were located in the PubMed search. The following characterizations derive from clinical observations, case reports, and medical literature.

**Dose-dependent "plateau" model:**
DXM recreational use is traditionally described using a four-plateau model based on dose ranges. This model is widely referenced in harm reduction literature and user reports but has not been formally validated in controlled human studies. The existing dose data in the brief (Threshold: 75 mg, Light: 100–200 mg, Common: 200–400 mg, Strong: 400–700 mg, Heavy: 700+ mg) are consistent with community consensus and pharmacology literature.

**From overdose/clinical case literature (at supratherapeutic doses):**
StatPearls [Ref 22] reports that at doses >4 mg/kg:
- Up to 64% experience euphoria and CNS effects
- 20% sensation of being "drunk" or "high"
- 17% nausea and vomiting
- 15% nystagmus
- 15% dizziness

At higher doses: visual hallucinations, persecutory delusions, agitation, disorientation. DXM overdose can produce a toxidrome combining dissociation, serotonin excess, and CNS depression.

**Dissociative mechanisms:**
At supratherapeutic doses, DXM and particularly its metabolite dextrorphan produce phencyclidine-like behavioral effects due to NMDA antagonism. The metabolite DXO (with Ki 0.9 µM at NMDA/PCP site) is primarily responsible for dissociative intoxication Miller (2005 [Ref 7]). CYP2D6 "poor metabolizer" individuals may accumulate more parent DXM relative to DXO, producing a somewhat different pharmacological profile.

**Duration:** Onset 30–120 minutes, peak 3–6 hours, total duration 8–12 hours (oral). Duration is strongly influenced by CYP2D6 phenotype — poor metabolizers experience longer and more intense effects. After-effects documented up to 24 hours.

**Effect domains documented in literature:**
- Perceptual: visual and auditory distortions, derealization, dissociation (confirmed by case reports and overdose literature)
- Cognitive: confusion, amnesia, thought disorganization
- Physical: nystagmus, ataxia, motor impairment, nausea, tachycardia, hyperthermia at high doses
- Affective: euphoria at moderate doses; dysphoria, agitation at high doses

---

## Safety & Toxicity

**LD50:** Not established in humans. Exact toxic dosage is unknown (consistent with brief seed data). Animal data not retrieved in this search pass.

**Toxicity thresholds (clinical guidance):**
Chyka et al. (2007 [Ref 28]) evidence-based consensus guideline:
- **5–7.5 mg/kg:** Increased monitoring recommended
- **>7.5 mg/kg:** Emergency department referral recommended
- **>4 mg/kg:** Up to 64% of patients experience psychoactive effects

**Overdose presentations:**
- *Moderate overdose:* Nystagmus, dizziness, dysphoria, hallucinations, agitation
- *Severe overdose:* Refractory status epilepticus, CNS depression, respiratory depression, hyperthermia, rhabdomyolysis, serotonin toxidrome

**Published case reports:**
- Okamoto et al. (2025 [Ref 4]): 21-year-old woman ingested 5,600 mg (≈20 × 280 mg tablets). Serum DXM = 5.8 mg/L on admission. Refractory status epilepticus, cranial nerve reflex loss. Recovered fully by day 9. Authors concluded DXM (not DXO) was responsible for symptoms, suggesting CYP2D6 inhibition by co-ingested medications amplified DXM toxicity.
- Shimozawa et al. (2023 [Ref 5]): 19-year-old female ingested 111 tablets → shock and convulsions → intensive care → recovery.

**Key toxicity mechanisms:**
1. **Serotonin syndrome** — life-threatening toxicity from SERT inhibition combined with serotonergic co-medications. Most dangerous interaction [Ref 22].
2. **CNS/respiratory depression** — at very high doses, especially compounded by CNS depressants
3. **Hyperthermia** — from serotonin excess and psychomotor agitation
4. **Rhabdomyolysis** — from prolonged agitation/seizures

**CYP2D6 impact on toxicity:** Poor metabolizers and individuals taking CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) accumulate much higher DXM plasma levels from the same dose, dramatically increasing toxicity risk [Ref 4, Ref 18].

**Psychological risks:** Acute psychosis with persecutory delusions reported at high doses. Chronic misuse associated with psychosis, depression, and cognitive dysfunction Miller (2005 [Ref 7]).

---

## Harm Reduction

**Published evidence-based protocols:**

Chyka et al. (2007 [Ref 28]) evidence-based consensus guideline for out-of-hospital DXM poisoning management:
1. Refer to ED for suicidal intent, intentional abuse, or suspected malicious use
2. Refer to ED if >mild symptoms (more than infrequent vomiting or light somnolence)
3. Ingestion 5–7.5 mg/kg: poison center follow-up every 2 hours × 4 hours
4. Ingestion >7.5 mg/kg: ED referral
5. If taking MAOIs or SSRIs: follow up every 2 hours × 8 hours (serotonin syndrome risk)
6. Asymptomatic and >4 hours post-ingestion: observe at home
7. Do NOT induce emesis
8. Do NOT use activated charcoal at home
9. Consider naloxone for comatose patients with respiratory depression (opioid-like effects at very high doses)
10. Benzodiazepines for seizures; benzodiazepines + external cooling for hyperthermia/serotonin syndrome

**Critical contraindications:**
- **MAOIs:** Absolute contraindication; risk of fatal serotonin syndrome. Minimum 14-day washout required [Ref 22]
- **SSRIs/SNRIs:** Caution; serotonin syndrome risk
- **CYP2D6 inhibitors:** Dramatically raise DXM plasma levels; high-risk co-medications include paroxetine, fluoxetine, bupropion
- **CNS depressants (alcohol, GHB, benzodiazepines, opioids):** Additive CNS/respiratory depression

**Pharmacogenomic testing:** Identifying CYP2D6 poor metabolizer status before use would substantially reduce individual risk, but is not standard practice for OTC use.

**Age-specific concerns:** Adolescents and young adults are the primary population at risk for DXM misuse. Restricted OTC sale to adults (18+) in 20+ US states [Ref 25].

**Testing and identification:** DXM is not detected by standard opioid immunoassay drug screens. Some urine drug screens will detect dextrorphan. Misidentification as PCP is possible on some immunoassay screens due to structural similarities [Ref 16].

---

## Tolerance & Dependence

**Tolerance:**
Tolerance develops with repeated and prolonged use. DXM cross-tolerates with other NMDA antagonist dissociatives (ketamine, PCP). The brief's tolerance data (buildup with prolonged use; half-life 5 days; full reset 1.5 weeks; cross-tolerance: dissociatives) is not directly confirmed by published primary sources retrieved — these values appear to reflect community consensus rather than controlled study.

⚠️ **FLAG:** The "5-day half-life" listed for tolerance is distinct from the pharmacokinetic half-life of DXM itself (2–3h in EMs, 15–20h in PMs). This likely refers to functional tolerance receptor reset time, not drug elimination. No published primary source was found quantifying DXM tolerance half-life or reset time. Community consensus values; not verifiable from retrieved literature.

**Dependence:**
Physical and psychological dependence with chronic DXM use is documented in case reports:
- Miller (2005 [Ref 7]): Described a case of DXM dependence with substance-induced psychosis and withdrawal syndrome. Withdrawal features consistent with NMDA antagonist discontinuation.
- Mutschler et al. (2010 [Ref 6]): Documented increasing abuse cases in Germany with dependence syndrome. DXM available without prescription since 1954; alarming increase in misuse reports.

DXM has demonstrated properties associated with addiction: reward system activation (dopaminergic), tolerance development, and withdrawal upon cessation. In animal models, DXM attenuated morphine and nicotine dependence behaviors, suggesting it interacts with addiction circuitry Huang et al. (2023 [Ref 34]).

The brief's characterization of "moderate" physical and psychological dependence liability is consistent with the literature, though no formal dependence rating scale study was retrieved.

---

## Interactions

**Serotonin syndrome (highest severity):**
DXM inhibits SERT, and its metabolite DXO has additional serotonergic activity. Combined with serotonergic drugs, fatal serotonin syndrome is possible:
- **MAOIs:** Absolute contraindication — most dangerous combination. MAO inhibition combined with DXM's SERT inhibition causes serotonin accumulation. Fatal interactions are documented (case literature). 14-day washout required [Ref 22, Ref 28].
- **Tramadol:** Tramadol is both a weak mu-opioid agonist and a SERT/NET inhibitor. Combined with DXM's SERT inhibition → additive serotonin syndrome risk. The brief lists this as "lethal." The mechanism is serotonin syndrome. No specific primary case report found in this search, but the pharmacological basis is established.
- **MDMA:** MDMA is a potent serotonin releaser and SERT inhibitor. Combined with DXM → significant serotonin syndrome risk. Brief lists as "lethal." Mechanism is additive serotonergic action.
- **AMT (alpha-methyltryptamine):** Serotonergic compound; combined with DXM → serotonin syndrome risk. Brief lists as "lethal."
- **SSRIs:** Serotonin syndrome risk. Also: SSRIs that inhibit CYP2D6 (paroxetine, fluoxetine) substantially raise DXM plasma levels, amplifying both serotonergic and NMDA antagonist effects [Ref 7, Ref 22].

**CNS depression (high severity):**
- **Alcohol (ethanol):** CNS depressant + DXM's CNS effects → additive CNS/respiratory depression. Brief lists as "lethal." Mechanism: additive CNS depression, increased aspiration risk.
- **GHB/GBL:** CNS depressants; combined with DXM → severe CNS/respiratory depression. Brief lists as "lethal."
- **PCP:** Both are NMDA antagonists acting at the same PCP/MK-801 binding site. Additive dissociation; unpredictable and extreme CNS effects. Brief lists as "lethal."

**Cardiovascular risk:**
- **Cocaine:** Cocaine is a CNS stimulant with cardiac arrhythmia potential. DXM + cocaine carries arrhythmia risk and potential serotonergic interaction. Brief lists as "dangerous."

**Pharmacokinetic interactions (CYP2D6):**
Any drug that strongly inhibits CYP2D6 will raise DXM levels significantly:
- **Bupropion:** Strong CYP2D6 inhibitor; >100-fold increase in DXM exposure when combined [Ref 2] — this is the basis of the Auvelity formulation (intended)
- **Paroxetine, fluoxetine:** Strong CYP2D6 inhibitors; also serotonergic → dual risk
- **Quinidine:** Strong CYP2D6 inhibitor; used therapeutically in Nuedexta to raise DXM bioavailability [Ref 18]

**Cannabis:** Brief lists interaction as "unknown." No published human data on DXM + cannabis interaction retrieved. THC may have additive CNS effects and could affect CYP enzyme activity, but no specific interaction study found.

---

## Legal Status

**United States (Federal):**
DXM is **unscheduled** — not listed under the Controlled Substances Act (CSA) of 1970. It is excluded from federal scheduling and remains an approved OTC drug with no federal age restriction [Ref 25].

**United States (State):**
Over 20 states have enacted laws restricting sale of DXM-containing products to individuals under 18 years of age. States with age-restriction laws include California, New York, Texas, Florida, Ohio, and others [Ref 25]. Implementation varies: some states require ID verification for any purchaser appearing under 25–27 years old.

**International:**
- **Russia:** Schedule III controlled substance [Ref 26]
- **Sweden and Norway:** Not available (unavailable OTC) [Ref 26]
- **Denmark:** Available by prescription only [Ref 26]
- **Australia:** S2 (pharmacy medicine, restricted OTC availability under TGA scheduling) [Ref 26]
- **United Kingdom:** Available OTC; general sale [Ref 26]
- **Canada:** Available OTC [Ref 26]
- **France:** Not generally available OTC in products for recreational-range dosing [Ref 26]

⚠️ **FLAG:** International legal status data is primarily web-retrieved from secondary sources (Wikipedia, Erowid). Should be verified against official regulatory databases for each jurisdiction before publication.

---

## Clinical Trials

**Completed/active trials of DXM-containing formulations:**

1. **NCT04608396** — MERIT trial; Phase 2; Axsome Therapeutics; DXM/bupropion (AXS-05) for treatment-resistant depression and MDD; COMPLETED
2. **NCT04947553** — Phase 3; Axsome Therapeutics; AXS-05 for Alzheimer's disease agitation; COMPLETED
3. **NCT01584440** — Phase 2; Avanir Pharmaceuticals; AVP-923 (DXM/quinidine) for agitation in Alzheimer's disease; COMPLETED
4. **NCT00021697** — Phase 3; Avanir Pharmaceuticals; AVP-923 for pseudobulbar affect (PBA) in ALS; COMPLETED — this was the pivotal trial leading to Nuedexta approval
5. **NCT01188265** — Phase 3; National Cheng-Kung University Hospital; Add-on DXM in bipolar disorders; COMPLETED (Taiwan RCTs, see Ref 37, 38)
6. **NCT01553435** — NMDA antagonist DXM for opioid analgesia/tolerance in pediatric ICU patients; UNKNOWN status
7. **NCT02534038** — Phase 2; Avanir; AVP-786 (deuterated DXM/quinidine) for disinhibition syndrome; TERMINATED

**Note:** DXM/quinidine (Nuedexta) received FDA approval in 2010 for PBA following the pivotal PRISM II trial (NCT00021697 related) Muneer et al. (2026 [Ref 12]). DXM/bupropion (Auvelity/AXS-05) received FDA approval in August 2022 for MDD in adults Chaki & Watanabe (2023 [Ref 24]).

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. Proceeding with standard research.

---

## Gaps & Flags

### Data Absent from Retrieved Sources:
1. **SMILES string:** Not returned by PubChem API call. Available at PubChem CID 5360696 — generation agent should retrieve directly.
2. **Protein binding percentage:** Not obtained (DrugBank returned 403). DrugBank lists DB00514 for DXM — should be retrieved.
3. **Volume of distribution (Vd):** Not quantified from primary sources retrieved.
4. **Tmax:** Specific Tmax values not found in retrieved studies. Likely 2–3 hours based on kinetic profiles but needs primary source.
5. **LD50 in humans or animals:** Not retrieved. Noted as unknown in published literature.
6. **Controlled human dose-response studies:** No formal psychoactive dose-response studies in healthy volunteers found. The 4-plateau recreational model is community-derived, not formally validated.
7. **DXM protein binding:** Missing from all retrieved sources.

### Flags for Editorial Review:
1. **⚠️ Mu-opioid receptor agonist classification:** The brief lists "Mu-opioid receptor agonist" as a pharmacological class. Published literature (StatPearls, DXM pharmacology texts) consistently states DXM lacks meaningful mu-opioid activity. DXM was specifically developed as a NON-narcotic antitussive. Lauterbach (2011 [Ref 29]) does mention weak mu-opioid receptor interactions. This classification appears incorrect and should be removed or severely qualified. **Safety-critical if it leads users to treat DXM as having opioid-like properties.**

2. **⚠️ Interaction severity designations (lethal):** The brief labels multiple interactions as "lethal" (Alcohol, PCP, GHB, GBL, MDMA, AMT, Tramadol). While these are legitimately serious interactions:
   - "Lethal" for Alcohol should be "dangerous to severe" — CNS depression is serious but not inherently lethal at typical recreational doses
   - "Lethal" for tramadol, MDMA, AMT reflects serotonin syndrome risk, which is accurate for severe cases
   - "Lethal" for PCP reflects extreme synergistic dissociation — accurate
   - No specific fatality case reports were retrieved to directly verify each "lethal" designation. These severity levels are supported by mechanistic reasoning but not confirmed individual case-by-case in the retrieved literature.

3. **⚠️ Tolerance data ("5-day half-life," "1.5-week full reset"):** These values appear to reflect community consensus rather than controlled pharmacological studies. No primary source was found validating these specific tolerance timelines.

4. **⚠️ Dose range not validated by controlled studies:** The plateau-based dose model (Threshold 75 mg, Light 100–200 mg, etc.) is derived from user reports and community consensus. No double-blind controlled dose-response study in human volunteers was found in the retrieved literature. These values appear reasonable based on pharmacology but cannot be cited to primary research.

5. **⚠️ Duration data:** The brief's duration data (onset 30–120 min, peak 3–6h, total 8–12h) is pharmacologically plausible but strongly CYP2D6-phenotype dependent. Duration for poor metabolizers would be significantly longer. A CYP2D6 phenotype caveat should be added to all duration data.

6. **⚠️ DXM availability as antitussive in children:** DXM-containing products were voluntarily withdrawn for use in children under 4 in the US (2007 FDA advisory), but this regulatory history was not verified through a primary source in this search. Warrants verification.

7. **Cannabis interaction labeled "unknown":** No published human data found. Warrants a note that THC may theoretically potentiate CNS effects and that no interaction studies exist.